Login Register Cart 0
Generic placeholder image

The International Journal of Gastroenterology and Hepatology Diseases

Editor-in-Chief

ISSN (Print): 2666-2906
ISSN (Online): 2666-2914

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease

Author(s): Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem and Amirhossein Nafari*

Volume 1, Issue 1, 2022

Published on: 26 April, 2022

Article ID: e240122200473 Pages: 8

DOI: 10.2174/2666290601666220124111511

conference banner
Abstract

Objective: Immunity-related issues are the main concerns of patients undergoing inflammatory bowel disease (IBD) treatment. The treatment of IBD during the last decade has evolved due to the ever-increasing utilization of immunomodulators, which has caused the potential of contracting opportunistic infections to become the main immunity concern for patients affected by IBD.

Methods: Studies on opportunistic infections in patients with IBD identified in databases such as Google Scholar, PubMed, and Scopus were reviewed and included.

Results: IBD patients are a high-risk population for opportunistic infections, with age being a significant factor. The primary therapy for IBD patients includes the suppression of the immunity system, together with immunodeficiency and biological treatments, which, first of all, must be standardized. Since treatment with suppressive medicine, which is the original method for curing IBD, causes viral infections and the growth of various bacteria, factors suppressing the body's immunity system must be temporarily suspended, or the consumption dosage of sensitive antibiotics should be reduced. Biological treatment and anti-integrin antibodies will lead to the danger of being affected by opportunistic infections in patients with IBD.

Conclusion:Worldwide research society must conduct further research into a therapeutic strategy for IBD patients to reduce susceptibility and the risk of opportunistic infection. Information about how these individuals and the medicines they were given reacted to different infections and more detailed clinical observations are required.

Keywords: Inflammatory bowel disease, Crohn's disease, ulcerative colitis, opportunistic infections, therapeutic strategy, intestinal microbiota.

Graphical Abstract

[1]
Fuehner, T.; Ernst, D.; Greer, M.; Gottlieb, J.; Welte, T. Opportunistic infections in the immunocompromised host; ERS Handbook of Respiratory Medicine, 2019, p. 400.
[http://dx.doi.org/10.1183/9781849840798.008218]
[2]
Dave, M.; Purohit, T.; Razonable, R.; Loftus, E.V., Jr Opportunistic infections due to inflammatory bowel disease therapy. Inflamm. Bowel Dis., 2014, 20(1), 196-212.
[http://dx.doi.org/10.1097/MIB.0b013e3182a827d2] [PMID: 24051931]
[3]
Glassner, K.L.; Abraham, B.P.; Quigley, E.M.M. The microbiome and inflammatory bowel disease. J. Allergy Clin. Immunol., 2020, 145(1), 16-27.
[http://dx.doi.org/10.1016/j.jaci.2019.11.003] [PMID: 31910984]
[4]
Rubin, D.C.; Shaker, A.; Levin, M.S. Chronic intestinal inflammation: Inflammatory bowel disease and colitis-associated colon cancer. Front. Immunol., 2012, 3, 107.
[http://dx.doi.org/10.3389/fimmu.2012.00107] [PMID: 22586430]
[5]
Alatab, S.; Sepanlou, S.G.; Ikuta, K.; Vahedi, H.; Bisignano, C.; Safiri, S.; Sadeghi, A.; Nixon, M.R.; Abdoli, A.; Abolhassani, H.; Alipour, V.; Almadi, M.A.H.; Almasi-Hashiani, A.; Anushiravani, A.; Arabloo, J.; Atique, S.; Awasthi, A.; Badawi, A.; Baig, A.A.A.; Bhala, N.; Bijani, A.; Biondi, A.; Borzì, A.M.; Burke, K.E.; Carvalho, F.; Daryani, A.; Dubey, M.; Eftekhari, A.; Fernandes, E.; Fernandes, J.C.; Fischer, F.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hasanzadeh, A.; Hashemian, M.; Hay, S.I.; Hoang, C.L.; Househ, M.; Ilesanmi, O.S.; Jafari Balalami, N.; James, S.L.; Kengne, A.P.; Malekzadeh, M.M.; Merat, S.; Meretoja, T.J.; Mestrovic, T.; Mirrakhimov, E.M.; Mirzaei, H.; Mohammad, K.A.; Mokdad, A.H.; Monasta, L.; Negoi, I.; Nguyen, T.H.; Nguyen, C.T.; Pourshams, A.; Poustchi, H.; Rabiee, M.; Rabiee, N.; Ramezanzadeh, K.; Rawaf, D.L.; Rawaf, S.; Rezaei, N.; Robinson, S.R.; Ronfani, L.; Saxena, S.; Sepehrimanesh, M.; Shaikh, M.A.; Sharafi, Z.; Sharif, M.; Siabani, S.; Sima, A.R.; Singh, J.A.; Soheili, A.; Sotoudehmanesh, R.; Suleria, H.A.R.; Tesfay, B.E.; Tran, B.; Tsoi, D.; Vacante, M.; Wondmieneh, A.B.; Zarghi, A.; Zhang, Z-J.; Dirac, M.; Malekzadeh, R.; Naghavi, M. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 2020, 5(1), 17-30.
[http://dx.doi.org/10.1016/S2468-1253(19)30333-4] [PMID: 31648971]
[6]
Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; Sung, J.J.Y.; Kaplan, G.G. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet, 2017, 390(10114), 2769-2778.
[http://dx.doi.org/10.1016/S0140-6736(17)32448-0] [PMID: 29050646]
[7]
Franchimont, D.; Vermeire, S.; El Housni, H.; Pierik, M.; Van Steen, K.; Gustot, T.; Quertinmont, E.; Abramowicz, M.; Van Gossum, A.; Devière, J.; Rutgeerts, P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut, 2004, 53(7), 987-992.
[http://dx.doi.org/10.1136/gut.2003.030205] [PMID: 15194649]
[8]
Imperatore, N.; Foggia, M.; Rispo, A.; Patturelli, M.; Calabrese, G.; Testa, A.; Nardone, O.; Pellegrini, L.; Guarino, A.D.; Ricciolino, S.; Tosone, G.; Castiglione, F. P139 prevalence of infections in patients affected by inflammatory bowel disease treated with anti-TNF-α agents: a single-centre experience. J. Crohn’s Colitis, 2020, 14(Suppl. 1), S206-S207.
[http://dx.doi.org/10.1093/ecco-jcc/jjz203.268]
[9]
Degasperi, E.; Caprioli, F.; El Sherif, O.; Back, D.; Colombo, M.; Aghemo, A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev. Gastroenterol. Hepatol., 2016, 10(12), 1373-1383.
[http://dx.doi.org/10.1080/17474124.2016.1246181] [PMID: 27718758]
[10]
Badia, E.; Barrio, J.; Fernández-Salazar, L.; Fuentes, A.; Hontoria, G.; Sicilia, B. P827 prevalence of viral hepatitis in patients with IBD: A multi-centre and population-based study. J. Crohn’s Colitis, 2018, 12(Suppl. 1), S534.
[http://dx.doi.org/10.1093/ecco-jcc/jjx180.954]
[11]
He, Y.; Xu, P.; Chen, Y.; Yang, R.; Chen, B.; Zeng, Z.; Chen, M. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int. J. Clin. Exp. Med., 2015, 8(5), 8078-8085.
[PMID: 26221373]
[12]
Andrade, P.; Santos-Antunes, J.; Rodrigues, S.; Lopes, S.; Macedo, G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J. Gastroenterol. Hepatol., 2015, 30(11), 1591-1595.
[http://dx.doi.org/10.1111/jgh.13001] [PMID: 25967740]
[13]
Pratt, P.K., Jr; David, N.; Weber, H.C.; Little, F.F.; Kourkoumpetis, T.; Patts, G.J.; Weinberg, J.; Farraye, F.A. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm. Bowel Dis., 2018, 24(2), 380-386.
[http://dx.doi.org/10.1093/ibd/izx001] [PMID: 29361083]
[14]
Tun, G.S.Z.; Raza, M.; Hale, M.F.; Lobo, A.J. Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. Ann. Gastroenterol., 2019, 32(1), 81-87.
[http://dx.doi.org/10.20524/aog.2018.0318] [PMID: 30598596]
[15]
Nahar, S.; Hokama, A.; Fujita, J. Clinical significance of cytomegalovirus and other herpes virus infections in ulcerative colitis. Pol. Arch. Intern. Med., 2019, 129(9), 620-626.
[http://dx.doi.org/10.20452/pamw.14835] [PMID: 31111828]
[16]
Serrero, M.; Peyrin-Biroulet, L.; Grimaud, J.C. IBD and HIV: “Dangerous Liaisons. Hepato-Gastro & Oncologie Digestive., 2017, 24(1), 34-41.
[http://dx.doi.org/10.1684/hpg.2016.1398]
[17]
Alzahrani, J.; Hussain, T.; Simar, D.; Palchaudhuri, R.; Abdel-Mohsen, M.; Crowe, S.M.; Mbogo, G.W.; Palmer, C.S. Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities. EBioMedicine, 2019, 46, 522-531.
[http://dx.doi.org/10.1016/j.ebiom.2019.07.027] [PMID: 31327693]
[18]
Schreiner, P.; Mueller, N.J.; Fehr, J.; Maillard, M.H.; Brand, S.; Michetti, P.; Schoepfer, A.; Restellini, S.; Vulliemoz, M.; Vavricka, S.R.; Juillerat, P.; Rogler, G.; Biedermann, L. Varicella zoster virus in inflammatory bowel disease patients: What every gastroenterologist should know. J. Crohn’s Colitis, 2020, jjaa132.
[http://dx.doi.org/10.1093/ecco-jcc/jjaa132] [PMID: 32592587]
[19]
Soh, H.; Chun, J.; Han, K.; Park, S.; Choi, G.; Kim, J.; Lee, J.; Im, J.P.; Kim, J.S. Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: A nationwide population-based study. Gut Liver, 2019, 13(3), 333-341.
[http://dx.doi.org/10.5009/gnl18304] [PMID: 30602222]
[20]
Sokol, H.; Leducq, V.; Aschard, H.; Pham, H.P.; Jegou, S.; Landman, C.; Cohen, D.; Liguori, G.; Bourrier, A.; Nion-Larmurier, I.; Cosnes, J.; Seksik, P.; Langella, P.; Skurnik, D.; Richard, M.L.; Beaugerie, L. Fungal microbiota dysbiosis in IBD. Gut, 2017, 66(6), 1039-1048.
[http://dx.doi.org/10.1136/gutjnl-2015-310746] [PMID: 26843508]
[21]
Tinsley, A.; Navabi, S.; Williams, E.D.; Liu, G.; Kong, L.; Coates, M.D.; Clarke, K. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm. Bowel Dis., 2019, 25(2), 369-376.
[http://dx.doi.org/10.1093/ibd/izy243] [PMID: 30020478]
[22]
Hosomi, S.; Watanabe, K.; Nishida, Y.; Yamagami, H.; Yukawa, T.; Otani, K.; Nagami, Y.; Tanaka, F.; Taira, K.; Kamata, N.; Tanigawa, T.; Shiba, M.; Watanabe, T.; Nagahara, H.; Maeda, K.; Fujiwara, Y. Combined infection of human herpes viruses: A risk factor for subsequent colectomy in ulcerative colitis. Inflamm. Bowel Dis., 2018, 24(6), 1307-1315.
[http://dx.doi.org/10.1093/ibd/izy005] [PMID: 29668948]
[23]
Stamatiades, G.A.; Ioannou, P.; Petrikkos, G.; Tsioutis, C. Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses, 2018, 61(6), 366-376.
[http://dx.doi.org/10.1111/myc.12753] [PMID: 29453860]
[24]
Stensvold, C.R.; van der Giezen, M. Associations between gut microbiota and common luminal intestinal parasites. Trends Parasitol., 2018, 34(5), 369-377.
[http://dx.doi.org/10.1016/j.pt.2018.02.004] [PMID: 29567298]
[25]
Liu, W.; Tang, S.; Zhao, Q.; Zhang, W.; Li, K.; Yao, W.; Gao, X. The α-D-glucan from marine fungus Phoma herbarum YS4108 ameliorated mice colitis by repairing mucosal barrier and maintaining intestinal homeostasis. Int. J. Biol. Macromol., 2020, 149, 1180-1188.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.01.303] [PMID: 32014479]
[26]
Byun, J.M.; Lee, C.K.; Rhee, S.Y.; Kim, H.J.; Im, J.P.; Park, D.I.; Eun, C.S.; Jung, S.A.; Shin, J.E.; Lee, K.M.; Cheon, J.H. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scand. J. Gastroenterol., 2015, 50(3), 312-320.
[http://dx.doi.org/10.3109/00365521.2014.1000960] [PMID: 25581784]
[27]
Kim, E.S.; Song, G.A.; Cho, K.B.; Park, K.S.; Kim, K.O.; Jang, B.I.; Kim, E.Y.; Jeon, S.W.; Lee, H.S.; Yang, C.H.; Lee, Y.K.; Lee, D.W.; Kim, S.K.; Kim, T.O.; Lee, J.; Kim, H.W.; Jee, S.R.; Park, S.J.; Kim, H.J. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J. Gastroenterol., 2015, 21(11), 3308-3316.
[http://dx.doi.org/10.3748/wjg.v21.i11.3308] [PMID: 25805938]
[28]
Agarwal, A.; Kedia, S.; Jain, S.; Gupta, V.; Bopanna, S.; Yadav, D.P.; Goyal, S.; Mouli, V.P.; Dhingra, R.; Makharia, G.; Ahuja, V. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest. Res., 2018, 16(4), 588-598.
[http://dx.doi.org/10.5217/ir.2018.00023] [PMID: 30301331]
[29]
Drevno, D.; Hickok, S.; Ali, S. P016 improving tuberculosis re screening in inflammatory bowel disease patients receiving biologic therapy: a single center quality improvement initiative. Inflamm. Bowel Dis., 2020, 26(Suppl. 1), S52-S53.
[http://dx.doi.org/10.1093/ibd/zaa010.132]
[30]
Sato, R.; Nagai, H.; Matsui, H.; Yamane, A.; Kawashima, M.; Higa, K.; Nakamura, S.; Ohshima, N.; Tamura, A.; Hebisawa, A. Ten cases of intestinal tuberculosis which were initially misdiagnosed as inflammatory bowel disease. Intern. Med., 2019, 58(14), 2003-2008.
[http://dx.doi.org/10.2169/internalmedicine.2361-18] [PMID: 30918188]
[31]
Qasem, A.; Naser, A.E.; Naser, S.A. The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn’s disease. Expert Rev. Anti Infect. Ther., 2017, 15(7), 637-643.
[http://dx.doi.org/10.1080/14787210.2017.1328276] [PMID: 28481651]
[32]
Singanayagam, A.; Glanville, N.; Cuthbertson, L.; Bartlett, N.W.; Finney, L.J.; Turek, E.; Bakhsoliani, E.; Calderazzo, M.A.; Trujillo-Torralbo, M.B.; Footitt, J.; James, P.L.; Fenwick, P.; Kemp, S.V.; Clarke, T.B.; Wedzicha, J.A.; Edwards, M.R.; Moffatt, M.; Cookson, W.O.; Mallia, P.; Johnston, S.L. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci. Transl. Med., 2019, 11(507), eaav3879.
[http://dx.doi.org/10.1126/scitranslmed.aav3879] [PMID: 31462509]
[33]
Abreu, C.; Rocha-Pereira, N.; Sarmento, A.; Magro, F. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review. World J. Gastroenterol., 2015, 21(21), 6491-6498.
[http://dx.doi.org/10.3748/wjg.v21.i21.6491] [PMID: 26074688]
[34]
Magro, F.; Gionchetti, P.; Eliakim, R.; Ardizzone, S.; Armuzzi, A.; Barreiro-de Acosta, M.; Burisch, J.; Gecse, K.B.; Hart, A.L.; Hindryckx, P.; Langner, C.; Limdi, J.K.; Pellino, G.; Zagórowicz, E.; Raine, T.; Harbord, M.; Rieder, F. European Crohn’s and Colitis Organisation [ECCO] (2017). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohn’s Colitis, 2017, 11(6), 649-670.
[http://dx.doi.org/10.1093/ecco-jcc/jjx008] [PMID: 28158501]
[35]
Schultz, B.M.; Paduro, C.A.; Salazar, G.A.; Salazar-Echegarai, F.J.; Sebastián, V.P.; Riedel, C.A.; Kalergis, A.M.; Alvarez-Lobos, M.; Bueno, S.M. A potential role of salmonella infection in the onset of inflammatory bowel diseases. Front. Immunol., 2017, 8, 191.
[http://dx.doi.org/10.3389/fimmu.2017.00191] [PMID: 28293241]
[36]
Liu, J.; Gu, Z.; Song, F.; Zhang, H.; Zhao, J.; Chen, W. Lactobacillus plantarum ZS2058 and Lactobacillus rhamnosus GG use different mechanisms to prevent salmonella infection in vivo. Front. Microbiol., 2019, 10, 299.
[http://dx.doi.org/10.3389/fmicb.2019.00299] [PMID: 30842764]
[37]
Mirsepasi-Lauridsen, H.C.; Vallance, B.A.; Krogfelt, K.A.; Petersen, A.M. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin. Microbiol. Rev., 2019, 32(2), e00060-e18.
[http://dx.doi.org/10.1128/CMR.00060-18] [PMID: 30700431]
[38]
Chennou, F.; Habouri, L.; Jantchou, P. A262 clostridium difficile infection in children with inflammatory bowel disease: A single center cross-sectional study. J. Can. Assoc. Gastroenterol., 2019, 2(Suppl. 2), 515-516.
[http://dx.doi.org/10.1093/jcag/gwz006.261]
[39]
Hirten, R.P.; Grinspan, A.; Fu, S.C.; Luo, Y.; Suarez-Farinas, M.; Rowland, J.; Contijoch, E.J.; Mogno, I.; Yang, N.; Luong, T.; Labrias, P.R.; Peter, I.; Cho, J.H.; Sands, B.E.; Colombel, J.F.; Faith, J.J.; Clemente, J.C. Microbial engraftment and efficacy of fecal microbiota transplant for clostridium difficile in patients with and without inflammatory bowel disease. Inflamm. Bowel Dis., 2019, 25(6), 969-979.
[http://dx.doi.org/10.1093/ibd/izy398] [PMID: 30852592]
[40]
Ananthakrishnan, A.N.; Donaldson, T.; Lasch, K.; Yajnik, V. Management of inflammatory bowel disease in the elderly patient: Challenges and opportunities. Inflamm. Bowel Dis., 2017, 23(6), 882-893.
[http://dx.doi.org/10.1097/MIB.0000000000001099] [PMID: 28375885]
[41]
D’Haens, G.R.; Slatkin, N.; Israel, R.; Heimanson, Z. P097 favorable safety profile for amiselimod, a selective s1p receptor modulator, in Crohn’s disease. Inflamm. Bowel Dis., 2020, 26(Suppl. 1), S1-S2.
[http://dx.doi.org/10.1093/ibd/zaa010.002]
[42]
Ferrante, M.; Feagan, B.G.; Panés, J.; Baert, F.; Louis, E.; Dewit, O.; Kaser, A.; Duan, W.R.; Gustafson, D.; Liao, X.; Wallace, K.; Kalabic, J.; D’Haens, G.R. OP27 Long-term safety and efficacy of risankizumab treatment in patients with crohn’s disease: final results from the phase 2 open-label extension study. J. Crohn’s Colitis, 2020, 14(Suppl. 1), S024-S025.
[http://dx.doi.org/10.1093/ecco-jcc/jjz203.026]
[43]
Zhao, M.; Lördal, M.; Langholz, E.; Knudsen, T.; Voutilainen, M.; Høivik, M.L.; Moum, B.; Saebo, B.; Haiko, P.; Malmgren, C.; Coskun, M.; Melberg, H.O.; Burisch, J. Høivik, Ml. et al. OP35 treatment outcomes of inflammatory bowel disease in the biological era-a nationwide retrospective cohort study in three nordic countries: Results from the trinordic study. J. Crohn’s Colitis, 2020, 14(Suppl. 1), S036-S037.
[http://dx.doi.org/10.1093/ecco-jcc/jjz203.034]
[44]
Naldini, G.; Sturiale, A.; Fabiani, B.; Giani, I.; Menconi, C. Micro-fragmented adipose tissue injection for the treatment of complex anal fistula: a pilot study accessing safety and feasibility. Tech. Coloproctol., 2018, 22(2), 107-113.
[http://dx.doi.org/10.1007/s10151-018-1755-8] [PMID: 29453515]
[45]
Pugliese, D.; Privitera, G.; Armuzzi, A. P477 Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of inflammatory bowel disease: The elderly cohort. J. Crohn’s Colitis, 2020, 14(Suppl. 1), S419-S422.
[http://dx.doi.org/10.1093/ecco-jcc/jjz203.606]
[46]
Gong, S.S.; Fan, Y.H.; Han, Q.Q.; Lv, B.; Xu, Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J. Gastroenterol., 2019, 25(18), 2240-2250.
[http://dx.doi.org/10.3748/wjg.v25.i18.2240] [PMID: 31143074]
[47]
Tretina, K.; Park, E.S.; Maminska, A.; MacMicking, J.D. Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease. J. Exp. Med., 2019, 216(3), 482-500.
[http://dx.doi.org/10.1084/jem.20182031] [PMID: 30755454]
[48]
Wang, X.; Bootsma, H.; Kroese, F.; Dijkstra, G.; Pringle, S. Senescent stem and transient amplifying cells in crohn’s disease intestine. Inflamm. Bowel Dis., 2020, 26(2), e8-e9.
[http://dx.doi.org/10.1093/ibd/izz295] [PMID: 31769481]
[49]
Malham, M.; Lilje, B.; Houen, G.; Winther, K.; Andersen, P.S.; Jakobsen, C. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease. Scand. J. Gastroenterol., 2019, 54(8), 969-975.
[http://dx.doi.org/10.1080/00365521.2019.1644368] [PMID: 31329473]
[50]
Rubin, D.T.; Dubinsky, M.C.; Panés, J.; Wu, D.C.; Lawendy, N.; Guo, X.; Lai, C.; Kwok, K.; Su, C.; Salese, L. DOP75 efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study. J. Crohn’s Colitis, 2020, 14(Suppl. 1), S112-S113.
[http://dx.doi.org/10.1093/ecco-jcc/jjz203.114]
[51]
Perry, C.; Kapur, N.; Barrett, T.A. Neeraj, Kapur PhD.; Terrence A, Barrett, MD. DPP-4 as a novel biomarker for inflammatory bowel disease: Is it ready for clinical use? Inflamm. Bowel Dis., 2020, 26(11), 1720-1721.
[http://dx.doi.org/10.1093/ibd/izz320] [PMID: 31913471]
[52]
deBruyn, J.C.C.; Soon, I.S.; Fonseca, K.; Feng, S.; Purtzki, M.; Goedhart, C.; Kuhn, S.; Vanderkooi, O.G.; Wrobel, I. Serologic status of routine childhood vaccines, cytomegalovirus, and Epstein-Barr virus in children with inflammatory bowel disease. Inflamm. Bowel Dis., 2019, 25(7), 1218-1226.
[http://dx.doi.org/10.1093/ibd/izy366] [PMID: 30551205]
[53]
Neurath, M.F. COVID-19 and immunomodulation in IBD. Gut, 2020, 69(7), 1335-1342.
[http://dx.doi.org/10.1136/gutjnl-2020-321269] [PMID: 32303609]
[54]
Al-Ani, A.H.; Prentice, R.E.; Rentsch, C.A.; Johnson, D.; Ardalan, Z.; Heerasing, N.; Garg, M.; Campbell, S.; Sasadeusz, J.; Macrae, F.A.; Ng, S.C.; Rubin, D.T.; Christensen, B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment. Pharmacol. Ther., 2020, 52(1), 54-72.
[http://dx.doi.org/10.1111/apt.15779] [PMID: 32348598]

Rights & Permissions Print Cite
Article Metrics
12
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy